INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure (INVESTED)

Request Access

Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial.

O. Vardeny, KyungMann Kim, J. Udell, et al.. (2020). JAMA. Cited 101 times. https://doi.org/10.1001/jama.2020.23649

High‐dose influenza vaccine to reduce clinical outcomes in high‐risk cardiovascular patients: Rationale and design of the INVESTED trial☆☆

O. Vardeny, J. Udell, J. Joseph, et al.. (2018). American Heart Journal. Cited 42 times. https://doi.org/10.1016/j.ahj.2018.05.007

Influenza Vaccine Immune Response in Patients With High-Risk Cardiovascular Disease

A. Peikert, B. Claggett, Jacob A. Udell, et al.. (2024). JAMA Cardiology. Cited 14 times. https://doi.org/10.1001/jamacardio.2024.0468

Association of post‐vaccination adverse reactions after influenza vaccine with mortality and cardiopulmonary outcomes in patients with high‐risk cardiovascular disease: the INVESTED trial

A. Peikert, B. Claggett, Kyungeun Kim, et al.. (2022). European Journal of Heart Failure. Cited 10 times. https://doi.org/10.1002/ejhf.2716

Temporal Association Among Influenza-Like Illness, Cardiovascular Events, and Vaccine Dose in Patients With High-Risk Cardiovascular Disease

Sheila M. Hegde, B. Claggett, Jacob A. Udell, et al.. (2023). JAMA Network Open. Cited 6 times. https://doi.org/10.1001/jamanetworkopen.2023.31284

Feasibility and Findings of Including Self-Identified Adult Congenital Heart Disease Patients in the INVESTED Trial

P. Dehghani, Varun Srivatsav, O. Vardeny, et al.. (2024). JACC: Advances. Cited 2 times. https://doi.org/10.1016/j.jacadv.2024.100897
NCPI Dataset Catalog
Feedback & Support
v0.10.0-b29ba7e